Celgene drops Morphosys's daratumumab-chasing anti-CD38 MAb
This article was originally published in Scrip
Executive Summary
Less than two years after laying out more than $150m in upfront payments and stock purchase, Celgene has handed back rights to Morphosys's anti-CD38 monoclonal antibody MOR202, which is under development for multiple myeloma. Morphosys said it was committed to continuing development of the product.